India to United States: Bortezomib Export Trade Route

The India to United States Bortezomib corridor is one of India's established pharmaceutical export routes, with 79 shipments documented worth a combined $4.0M USD. The route is dominated by EUGIA PHARMA SPECIALITIES LIMITED, which alone accounts for roughly 48% of all export value, reflecting the consolidated nature of India's bortezomib manufacturing sector.

Across 16 active suppliers, the average shipment value stands at $50.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 77% of all shipments, consistent with bortezomib's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 33 days port-to-port. The route has recorded an annual growth rate of 21.5%, placing it at rank #2 among India's top bortezomib export destinations globally.

On the import side, key buyers of Indian bortezomib in United States include EUGIA US LLC,, EUGIA US LLC, EVERSANA LIFE SCIENCE SERVICES LLC and 29 others. EUGIA US LLC, is the single largest importer with 13 shipments valued at $1.3M USD.

India's bortezomib exports to United States are driven primarily by a handful of large-scale manufacturers. EUGIA PHARMA SPECIALITIES LIMITED with 20 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 16 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, MSN LABORATORIES PRIVATE LIMITED, DR.REDDY'S LABORATORIES LTD — together account for 87% of total trade value on this route. The average shipment value of $50.6K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as bortezomib injection 3.5mg/vial sintetica ndc no:83090-008-01 and bortezomib for injection 3.5 mg/vial (bo , suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, EUGIA US LLC, is the largest importer with 13 shipments worth $1.3M USD — representing 34% of all bortezomib imports from India on this route. A total of 32 buyers are active on this corridor.